颖泰生物
(920819)
| 流通市值：52.65亿 | | | 总市值：53.44亿 |
| 流通股本：12.08亿 | | | 总股本：12.26亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,387,275,846.94 | 5,829,882,357.93 | 4,327,541,477.66 | 2,878,968,888.16 |
| 营业收入 | 1,387,275,846.94 | 5,829,882,357.93 | 4,327,541,477.66 | 2,878,968,888.16 |
| 二、营业总成本 | 1,390,914,399.31 | 5,982,883,377.41 | 4,453,921,595.05 | 2,911,718,084.59 |
| 营业成本 | 1,202,835,902.89 | 5,221,224,027.45 | 3,832,421,869.75 | 2,520,302,752.31 |
| 税金及附加 | 9,556,162.48 | 31,594,916.23 | 24,375,034.53 | 15,522,078.36 |
| 销售费用 | 20,156,761.92 | 95,811,650.5 | 61,708,849.01 | 42,560,381.07 |
| 管理费用 | 88,033,029.83 | 328,210,910.5 | 277,122,483.91 | 182,419,664.78 |
| 研发费用 | 39,977,073.76 | 173,428,698.2 | 129,541,520.16 | 85,066,760.84 |
| 财务费用 | 30,355,468.43 | 132,613,174.53 | 128,751,837.69 | 65,846,447.23 |
| 其中:利息费用 | 36,902,221.67 | 185,363,434.92 | 135,596,553.03 | 90,959,706.43 |
| 其中:利息收入 | 4,215,698.17 | 23,687,661.52 | 15,231,854.02 | 11,344,758.33 |
| 加:公允价值变动收益 | 977,768.91 | - | -586,961.84 | -1,186,596.58 |
| 加:投资收益 | 4,521,605.02 | -226,970,520.98 | -93,416,079.84 | -42,589,922.63 |
| 资产处置收益 | 2,978,650.61 | 3,207,056.93 | 4,085,095.09 | 3,636,501.14 |
| 资产减值损失(新) | 284,252.24 | -276,155,710.13 | -16,222,420.95 | -13,489,686 |
| 信用减值损失(新) | 401,294.25 | -3,728,302.1 | 129,377.27 | -1,690,187.02 |
| 其他收益 | 6,257,836.88 | 27,694,384.24 | 27,668,529.37 | 14,340,759.24 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 11,782,855.54 | -628,954,111.52 | -204,722,578.29 | -73,728,328.28 |
| 加:营业外收入 | 219,958.77 | 5,950,140.66 | 2,480,522.71 | 1,754,269.43 |
| 减:营业外支出 | 794,553.84 | 15,498,385.57 | 5,575,752.91 | 3,792,534.05 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 11,208,260.47 | -638,502,356.43 | -207,817,808.49 | -75,766,592.9 |
| 减:所得税费用 | 10,526,710.07 | -42,522,270.55 | -4,263,159.72 | 6,856,261.2 |
| 六、净利润 | 681,550.4 | -595,980,085.88 | -203,554,648.77 | -82,622,854.1 |
| 持续经营净利润 | 681,550.4 | -595,980,085.88 | -203,554,648.77 | -82,622,854.1 |
| 归属于母公司股东的净利润 | 2,348,404.41 | -587,333,739.05 | -198,170,380.37 | -79,384,075.67 |
| 少数股东损益 | -1,666,854.01 | -8,646,346.83 | -5,384,268.4 | -3,238,778.43 |
| (一)基本每股收益 | 0 | -0.48 | -0.16 | -0.06 |
| (二)稀释每股收益 | 0 | -0.48 | -0.16 | -0.06 |
| 八、其他综合收益 | 11,680,166.76 | -35,228,547.61 | -69,466,208.68 | -31,810,978.22 |
| 归属于母公司股东的其他综合收益 | 11,680,166.76 | -35,228,547.61 | -69,466,208.68 | -31,810,978.22 |
| 九、综合收益总额 | 12,361,717.16 | -631,208,633.49 | -273,020,857.45 | -114,433,832.32 |
| 归属于母公司股东的综合收益总额 | 14,028,571.17 | -622,562,286.66 | -267,636,589.05 | -111,195,053.89 |
| 归属于少数股东的综合收益总额 | -1,666,854.01 | -8,646,346.83 | -5,384,268.4 | -3,238,778.43 |
| 公告日期 | 2025-04-18 | 2025-04-18 | 2024-10-25 | 2024-08-19 |
| 审计意见(境内) | | 标准无保留意见 | | |